# Mana Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mana-bio

- Industry: Biotechnology
- Headquarters: Tel Aviv, Israel
- Website: www.mana.bio
- Total disclosed funding: $25M
- Latest round: Seed (Oct 10, 2023)
- Investors on record: 5

## About

Based in Israel, and founded in 2021, Mana Bio Ltd, also known as Mana.bio, provides Lipid Nanoparticle-based delivery systems for various therapies. In October 2023, the company raised USD 19.5 million in seed funding co-led by Base4 Capital, Andreessen Horowitz, and Technion - Israel Institute of Technology and returning investors NFX and Lion Bird Fund.

The company offers an artificial intelligence-based platform that combines machine learning and nanotechnology for the development of drug delivery systems for various therapies like vaccines and gene therapy. It helps develop gene therapy, which includes DNA and RNA-based therapeutics. Additionally, the firm also develops vaccines.

The company plans to use the October 2023 funding to facilitate the development of its proprietary AI LNP platform to improve the delivery of RNA and gene therapies to extrahepatic tissues in the body.

## Funding rounds

- Seed, Oct 10, 2023, $20M — Andreessen Horowitz, NFX, Technion - Israel Institute of Technology, Base4 Capital, Lion Bird Fund
- Seed, Oct 7, 2022, $5M — NFX, Lion Bird Fund

## Investors

- NFX (https://capitalatlas.ai/funds/nfx) — Seed
- Lion Bird Fund — Seed
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed
- Technion - Israel Institute of Technology — Seed
- Base4 Capital (https://capitalatlas.ai/funds/base4-capital) — Seed